Zeng Qiang, Liu Zhigang, Liu Ting
Department of Hematology, West China Hospital, Sichuan University, Chengdu, 610041, China.
BMC Cancer. 2020 Jan 28;20(1):59. doi: 10.1186/s12885-020-6550-z.
Programmed cell death ligand 1 (PD-L1) has already been detected in various carcinomas. In non-Hodgkin lymphoma (NHL), however, the prognostic value of PD-L1 overexpression remains unclear.
A meta-analysis of 2321 NHL patients from 12 studies was performed. Hazard ratios (HRs) with 95% confidence intervals (CIs) were used to evaluate the correlation between PD-L1 overexpression and prognosis of NHL, and odds ratios (ORs) with 95% CIs were used to assess the association of PD-L1 overexpression with clinicopathological factors.
The results showed that no significant difference between PD-L1 positive and negative groups was detected in NHL (HR: 1.40, 95% CI: 0.90-2.19; P = 0.137). Nevertheless, the results indicated that PD-L1 overexpression was associated with poor prognosis in the subtype of diffuse large B cell lymphoma (DLBCL) (HR: 1.70, 95% CI: 1.05-2.74; P = 0.031). We also performed subgroup analyses and meta-regression. The pooled OR showed that PD-L1 overexpression was associated with B symptoms, higher international prognostic index (IPI) score (3, 4, and 5 points) and Ann Arbor Stages III and IV.
The meta-analysis demonstrated that PD-L1 expression was not associated with prognosis of NHL but was associated with prognosis of DLBCL.
程序性细胞死亡配体1（PD-L1）已在多种癌症中被检测到。然而，在非霍奇金淋巴瘤（NHL）中，PD-L1过表达的预后价值仍不清楚。
对来自12项研究的2321例NHL患者进行了荟萃分析。采用风险比（HR）及95%置信区间（CI）评估PD-L1过表达与NHL预后之间的相关性，采用比值比（OR）及95%CI评估PD-L1过表达与临床病理因素之间的关联。
结果显示，NHL患者中PD-L1阳性组和阴性组之间未检测到显著差异（HR：1.40，95%CI：0.90-2.19；P = 0.137）。然而，结果表明，在弥漫性大B细胞淋巴瘤（DLBCL）亚型中，PD-L1过表达与预后不良相关（HR：1.70，95%CI：1.05-2.74；P = 0.031）。我们还进行了亚组分析和荟萃回归。汇总的OR显示，PD-L1过表达与B症状、较高的国际预后指数（IPI）评分（3、4和5分）以及Ann Arbor分期III和IV期相关。
荟萃分析表明，PD-L1表达与NHL的预后无关，但与DLBCL 的预后相关。
